Drug interaction study of befotertinib in healthy volunteers
This study checks how befotertinib, an experimental cancer drug, interacts with other drugs in healthy people. It helps make sure the drug is safe and works well when taken with other medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult aged 18 or older
- Your weight is at least 50 kg for men and 45 kg for women
- Your body mass index (BMI) is between 19 and 26
- You have no major health problems, especially heart, liver, or kidney issues
- You have not taken any prescription or over-the-counter drugs, herbal supplements, or vitamins in the past 14 days
- You agree to avoid alcohol, grapefruit juice, and too much caffeine during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how the experimental cancer drug vorolanib interacts with other medicines when taken together. It is for healthy people to help find the right dose and safety information before it is tested in patients.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
This study checks if itraconazole changes how the body processes HSK31858. Healthy volunteers are needed to help understand the safety and drug levels.
This study looks at how a new medicine (Flonoltinib Maleate) interacts with other drugs in healthy adults. It helps doctors understand safe dosing and potential effects before the medicine is tested in patients.
This study tests a new drug (clifutinib) in healthy volunteers to see how other common medicines (itraconazole, fluconazole, and efavirenz) affect its levels in the body. The results will help doctors understand how to dose clifutinib in future patients.
This study checks if a new oral drug, MDR-001, interacts safely with two common medicines (rifampin and itraconazole) when taken together. It's for healthy volunteers, and the results will help guide dosing for future patients.
Hear when a new DDI (Drug-Drug Interaction) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.